Pall Corporation Unveils Technical Innovation Center in China for Life Sciences

EAST HILLS, N.Y.–Pall Corporation (NYSE: PLL – News) today unveils its first Technical Innovation Center in China, Pall Filter (Beijing) Co., Ltd. and welcomes life sciences industry leaders and dignitaries to the grand opening event in Zhanjiang Hi-Tech Park in Shanghai. The Center, which incorporates a state-of-the-art filtration validation lab, provides comprehensive filtration technology support for the burgeoning Chinese biopharmaceuticals industry, one of the fast growing sectors of the country’s economy. It is the latest strategic addition to Pall’s global capabilities for the Asia-Pacific biopharmaceuticals market.

The facility houses one of the most advanced filtration validation labs in Asia. Certified to ISO9001, ISO14001 and OSHAS 18001 standards, the lab will help Pall customers meet the requirements of the new Chinese Good Manufacturing Practices (GMP’s) now in development, under which significantly increased regulatory guidelines are expected.

The Shanghai location, in the heart of China’s biopharmaceuticals industry, represents the eleventh filtration validation lab in Pall’s worldwide customer support network. The lab was created under the company’s global customer alignment initiative to address evolving biopharmaceutical customer needs locally.

The mission of Pall’s validation labs is to help its customers achieve first-time regulatory approval of their filtration validation packages. Pall’s broad experience with industry and regulatory agencies ensures compliance with current GMP’s and government requirements.

With more than sixty years of fluid management experience including filtration validation, Pall takes into account all critical product attributes and process parameters. The resulting filter validation package is tailored to meet customer specifications and is used as part of the regulatory approval process.

“We were receiving a growing stream of requests for validation assistance from our life sciences customers, even while the lab was still under construction,” said Kevin Liu Hai, Vice President of Pall China Life Sciences. “The need for a world-class filtration validation lab in the Chinese market is urgent. Our strategy is to deliver easily accessible, dependable, cost effective services and products to our Life Sciences customers in China to facilitate superior product development and accelerated growth.”

Biopharmaceutical Leadership in the Asia-Pacific Region

The debut of the Pall China Life Sciences Technical Innovation Center comes less than a year after the opening of Pall’s Life Sciences Center of Excellence in Bangalore, India in May 2007. The Bangalore Center was created to drive process optimization for the fast-growing Asia-Pacific global life sciences industry. It includes India’s most advanced proteomics laboratory to help customers speed the drug discovery process and enter the stringently regulated drug export market.

In Singapore, Pall’s ISO9001-certified Scientific and Laboratory Services (SLS) facility is another strategic component of the company’s global initiative to align with its customers worldwide. The world-class SLS capabilities are a cornerstone of Pall’s service commitment to help customers achieve the best operating efficiencies and product performance and meet all government requirements.

In addition to the SLS and R&D organizations throughout the world, Pall’s systems engineering capabilities help customers connect different parts of their process, making them more efficient, often in a smaller footprint and with lower energy consumption and environmental impact. These combined capabilities give customers a competitive edge and make Pall a valued partner.

Pall’s record of innovation and customer-driven technology solutions for the Asia-Pacific biopharmaceuticals industry is enhanced with the opening of the China Life Sciences Technical Innovation Center in Zhanjiang Hi-Tech Park.

Grand Opening

Grand opening activities commence on March 28, 2008 with a full-day seminar on pharmaceutical regulation and sterilizing filtration validation, to be held at the Dongjiao Hotel in Shanghai. The seminar, for key life sciences customers, industry leaders and regulators, will be led by Jerold Martin, Senior Vice President, Scientific Affairs, Pall BioPharmaceuticals, and Larry Scheer, Senior Product Manager, Pall Biosciences.

Special opening events will continue on March 29, 2008, with a tour of the Tech Center lab and a press conference for customers, industry officials and government representatives. Senior Pall executives, including Mr. Liu Hai and Eric Garnier, President, Pall Life Sciences, Rest of Asia Region, will be available for interviews following the ceremony.

About Pall Corporation

Pall Corporation is the global leader in the expanding field of filtration, separation and purification. Pall is organized into two businesses: Industrial and Life Sciences. These businesses provide leading-edge products to meet the demanding needs of customers in energy, electronics, biotechnology, pharmaceutical, transfusion medicine, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2007 were $2.2 billion. The Company is headquartered in East Hills, New York and has extensive operations around the world. For more information visit Pall at

Editors’ Note: Photographs of Pall’s new Technical Innovation Center in Shanghai can be found at:

< | >